Scalp angiosarcoma treated with linear accelerator-based boron neutron capture therapy: A report of two patients.

ABSTRACT:

Purpose

This study reports the first-in-human use of a linear accelerator-based boron neutron capture therapy (BNCT) system and the first treatment of patients with scalp-angiosarcoma with accelerator-based BNCT.

Patients and methods

A single-center open-label phase I clinical trial has been conducted using the system since November 2019. Patients with a localized node-negative scalp-angiosarcoma along with the largest diameter of the tumor ≤ 15 cm who refused primary surgery and chemotherapy were enrolled. After administration of boronophenylalanine (BPA), a single treatment of BNCT with the maximum dose delivered to the skin being 12 Gy-Eq was performed. The safety and effectiveness of accelerator-based BNCT therapy for localized scalp angiosarcoma were evaluated.

Resul

SUBMITTER: Igaki H 

PROVIDER: S-EPMC8892501 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature